Authors
Kathleen Chiotos, Molly Hayes, David W Kimberlin, Sarah B Jones, Scott H James, Swetha G Pinninti, April Yarbrough, Mark J Abzug, Christine E MacBrayne, Vijaya L Soma, Daniel E Dulek, Surabhi B Vora, Alpana Waghmare, Joshua Wolf, Rosemary Olivero, Steven Grapentine, Rachel L Wattier, Laura Bio, Shane J Cross, Nicholas O Dillman, Kevin J Downes, Kathryn Timberlake, Jennifer Young, Rachel C Orscheln, Pranita D Tamma, Hayden T Schwenk, Philip Zachariah, Margaret Aldrich, David L Goldman, Helen E Groves, Gabriella S Lamb, Alison C Tribble, Adam L Hersh, Emily A Thorell, Mark R Denison, Adam J Ratner, Jason G Newland, Mari M Nakamura
Publication date
2020/12/1
Journal
Journal of the Pediatric Infectious Diseases Society
Volume
9
Issue
6
Pages
701-715
Publisher
Oxford University Press
Description
Background
Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics.
Methods
A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys, a set of guidance statements was developed and refined based on review of best available evidence and expert opinion.
Results
Given the typically mild course of pediatric COVID-19, supportive care alone is suggested for the overwhelming majority of cases. The panel suggests a decision-making framework for antiviral therapy that …
Scholar articles
K Chiotos, M Hayes, DW Kimberlin, SB Jones… - Journal of the Pediatric Infectious Diseases Society, 2020
K Chiotos, M Hayes, DW Kimberlin, SB Jones… - Journal of the Pediatric Infectious Diseases Society, 2021